NYULH and NYUWS facilities combined support multiple rodent species including mice, rats, singing mice, zebra finches, and gerbils, large animal species such as pigs, non-human primates and rabbits and a variety of aquatic species.

NYULH consists of 4 central and 27 satellite facilities comprising 47,554 + sq. ft. Notable features include three rodent barrier facilities, a large animal housing, surgical suite and necropsy area, ABLS- 2 and ABSL-3 housing, as well as satellite facilities supporting zebrafish and Xenopus species.

NYUWS consists of 2 central and 5 satellite facilities comprising 10,933 sq. ft. Notable features include 2 rodent barriers, 3 non-human primate housing facilities for adult, juvenile and infant animals, a large animal surgical suite, diagnostic imaging equipment and 3 aquatic suites for housing Blind Cave fish, zebrafish and Aplysia californica. NYU also provides veterinary oversight for the multi-species fish facility located at NYU-Brooklyn Polytechnical Institute.

NYULH and NYUWS also have access to ancillary supporting core facilities such as the Preclinical Imaging Core which contains state-of-the art rodent and small animal imaging technologies small, a transgenic production facility, a rodent behavioral core, and a large animal MRI facility.

Regeneron Pharmaceuticals, Inc is located in Tarrytown, NY and can be reached using the NYC Metro North train lines. Transportation costs to Regeneron are included within trainee’s stipend. Regeneron Pharmaceuticals Inc. research animal facilities consist of five main facilities. The B5-3 Research Animal Facility (RAF) is the largest, 23,288 sq. ft. The B4-1 Mouse Production Facility (MPF) is 6,191 sq ft. The B4-2 Research Animal Facility (RAF) is 8,604 sq. ft. The Building 9 research animal vivarium is a new, self-contained state of the art facility with a net area of 56,000 square foot. This facility exclusively houses laboratory mice and includes rooms with exclusion barrier and conventional conditions, a quarantine room, procedure rooms, imaging suites, necropsy rooms, a large fully automated, efficient cage wash area with two tunnel washers, a rack washer, bedding dispensers and disposals, two large walk-in autoclave units, dedicated storage locations for food, bedding, and equipment and other research support areas. This facility provides space for the housing of over 100,000 mice either in individually ventilated caging systems or in shoeboxes in semi-rigid isolators. All of the facilities are under the management and oversight of Vivarium Operations. Supporting core facilities include small animal imaging, a transgenic production facility, isolator housing units and comprehensive surgical facilities.

New York University Washington Square (NYUWS), NYU Langone Health (NYULH) and Regeneron Pharmaceuticals, Inc. are proud to support an American College of Laboratory Animal Medicine (ACLAM) recognized three year post-doctoral training program in Laboratory Animal Medicine. The combined NYU-Regeneron training program is led by nine ACLAM boarded veterinarians and three ACVP boarded veterinary pathologists While rotating between the three supporting institutions veterinary postdocs will be exposed to a diversity of species, including primary, secondary, and tertiary species as defined in the ACLAM Role Delineation Document. Veterinary postdocs will also get to experience and appreciate organizational, managerial and operational differences between the three institutions. The combination of experiences ensures that postdocs are provided with a dynamic training experience that will help prepare them for the many career paths available in laboratory animal medicine.

To successfully meet all training objectives the NYU-Regeneron training program is divided into four fundamental components. Scheduled didactic training, the first component, which occurs weekly throughout the 3-year training program. Didactic training sessions are designed to provide trainees with the knowledge base needed to obtain Diplomate status in the American College of Laboratory Animal Medicine.

Laboratory animal clinical training is the second training component and occurs throughout the training program on a rotation basis. Laboratory animal clinical training encompasses anesthesia, surgery, pre and post-operative care, necropsy, pathology, preventative medicine, husbandry, enrichment and behavior focusing on commonly used laboratory animal species.

Regulatory training is the third component of the training program. Postdoctoral fellows are expected to participate in at least one monthly IACUC meeting and will be assigned to participate either as an alternate member or in an observational role throughout the duration of the 3-year program. Postdocs will be expected to routinely review IACUC protocols and to discuss reviews with assigned veterinary IACUC mentors. Postdocs may also be asked to participate in semiannual inspections, regulatory and compliance meetings.

The fourth and final component of the NYU-Regeneron training program is the research rotation. During the research rotation postdoctoral fellows are allocated a period of 12 months to design and successfully execute a research project. An ACLAM-certified member of the program faculty will serve as the primary research mentor, or alternatively research mentorship will be assigned to a suitable faculty member willing and qualified to oversee the research project.

NYULH (an academic medical center) and NYUWS research, teaching, and testing programs include but are not limited to: neuroscience and behavior, microbiology, immunology, cancer, cardiology, surgery, diagnostic imaging, and endocrinology. The NYU School of Medicine, a division of NYULH, ranked No. 3 in the nation in U.S. News & World Report’s 2019 ‘Best Graduate Schools’ rankings for research.

Regeneron Pharmaceuticals, Inc. is a leading science-based, fully integrated biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, rheumatoid arthritis, and asthma.

Henry JA, Roble G, Steinbach J Proceed, but cautiously. J.Lab Anim (NY). 2014 Nov;43(11):392-3. doi: 10.1038/laban.645.